Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer.

Autor: Goldberg J; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., Qiao N; Department of Hematopoietic Biology & Malignancy, University of Texas MD Anderson Cancer Center, Houston, Texas., Guerriero JL; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Gross B; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., Meneksedag Y; Faculty of Medicine, Hacettepe University, Ankara, Turkey., Lu YF; McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas., Philips AV; Department of Hematopoietic Biology & Malignancy, University of Texas MD Anderson Cancer Center, Houston, Texas., Rahman T; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., Meric-Bernstam F; Department of Investigational Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Roszik J; Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas., Chen K; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jeselsohn R; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Tolaney SM; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Peoples GE; LumaBridge (formerly Cancer Insight), San Antonio, Texas., Alatrash G; Department of Hematopoietic Biology & Malignancy, University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Stem Cell Transplant and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas., Mittendorf EA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.

Publikováno v: Cancer research communications [Cancer Res Commun] 2024 Feb 22; Vol. 4 (2), pp. 496-504.